Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Selective BRAF Inhibitors Induce Marked T-cell Infiltration Into Human Metastatic Melanoma

J. Wilmott, G. Long, J. Howle, L. Haydu, R. Sharma, J. Thompson, R. Kefford, P. Hersey, R. Scolyer
Published 2011 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Purpose: To evaluate the effects of treatment with the potent mutant BRAF inhibitors GSK2118436 or vemurafenib (PLX4720) on immune responses to metastatic melanoma in tissues taken before and after treatment. Experimental Design: Thirty-seven tumor biopsies were collected from 15 patients with unresectable American Joint Committee on Cancer stage III or IV melanoma immediately before and approximately 7 days after the commencement of BRAF inhibitor treatment and at the time of tumor progression. Immunohistochemical staining was carried out on the biopsies using specific antibodies for CD8, CD4, CD20, CD1a, and Granzyme B. Results: Tumor infiltration by CD4+ and CD8+ lymphocytes increased markedly following BRAF inhibitor treatment (both ρ = 0.015). There was a correlation between the degree of tumor infiltration by CD8+ and Granzyme B–expressing lymphocytes in post–BRAF inhibitor–treated biopsies (r = 0.690 and ρ = 0.013). Increased intratumoral CD8+ lymphocyte expression was correlated with a reduction in tumor size and an increase in necrosis in posttreatment biopsies (r = −0.793, ρ = 0.011; and r = 0.761, ρ = 0.004, respectively). Conclusions: The increase in tumor-infiltrating lymphocytes induced by treatment with BRAF inhibitors provides strong support for conducting trials that combine BRAF inhibitors with immunotherapy in the hope of prolonging clinical responses. Clin Cancer Res; 18(5); 1386–94. ©2011 AACR.
This paper references
10.1007/s00262-009-0732-5
Treatment combinations targeting apoptosis to improve immunotherapy of melanoma
P. Hersey (2009)
10.1056/NEJMoa1002011
Inhibition of mutated, activated BRAF in metastatic melanoma.
K. Flaherty (2010)
Phase 1/2 study of GSK2118436, a selective inhibitor of V600 mutant (Mut) BRAF kinase: evidence of activity in melanoma brain metastases (Mets)
Gv Long (2010)
10.1016/s0190-9622(08)81857-9
Cutaneous melanoma.
V. Lees (1993)
10.1084/jem.20051848
The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells
H. Sumimoto (2006)
10.1056/NEJMoa1103782
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
P. Chapman (2011)
10.1158/1541-7786.MCR-06-0077
Role of the Mitogen-Activated Protein Kinase Signaling Pathway in the Regulation of Human Melanocytic Antigen Expression
M. Kono (2006)
10.1007/BF02967383
New guidelines to evaluate the response to treatment in solid tumors
P. Therasse (2000)
10.1056/NEJMoa1003466
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
10.1200/JCO.2008.20.9288
Predictors of competing mortality in advanced head and neck cancer.
L. Mell (2010)
10.1158/1078-0432.CCR-10-1911
The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations
B. Comin-Anduix (2010)
10.1016/j.ejca.2008.10.026
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E. Eisenhauer (2009)
10.1158/0008-5472.CAN-10-0118
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.
A. Boni (2010)
Clin Cancer Res Clinical Cancer Research American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from Published OnlineFirst December
(1394)
10.1016/S0140-6736(09)61397-0
Cutaneous melanoma in the era of molecular profiling
J. Thompson (2009)
10.1200/JCO.2010.32.4327
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
G. Long (2011)
10.1200/JCO.2011.29.15_SUPPL.8542
Morphologic and immunohistochemical (IHC) changes in metastatic melanoma (MM) tissue and associations with clinical outcome in patients (pts) on BRAF inhibitors (BRAFi).
G. Long (2011)
Phase 1/2 study of GSK2118436, a selective inhibitor of V600 mutant (Mut) BRAF kinase: evidence of activity in melanoma brain metastases (Mets)
LongGV (2010)
10.1002/ijc.23543
Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T‐lymphocytes and preserved MHC class I antigen expression
I. S. van Houdt (2008)
10.1200/JCO.2009.23.4799
Final version of 2009 AJCC melanoma staging and classification.
C. Balch (2009)
10.1038/sj.onc.1207785
B-RAF is a therapeutic target in melanoma
M. Karasarides (2004)
10.1056/NEJMoa1104621
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
C. Robert (2011)
10.1200/JCO.2010.28.15_SUPPL.8503
Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.
R. Kefford (2010)



This paper is referenced by
10.3978/j.issn.2305-5839.2015.08.06
Melanoma: oncogenic drivers and the immune system.
N. Karachaliou (2015)
BreastCare Immunomodulation via Chemotherapy and Targeted Therapy : A New Paradigm in Breast Cancer Therapy ?
John Stagga Fabrice Andreb Sherene Loic (2012)
10.1038/nrclinonc.2013.245
Mitigating the toxic effects of anticancer immunotherapy
Tara C. Gangadhar (2014)
10.1530/EJE-15-0957
ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma.
P. Brastianos (2016)
10.1016/j.phrs.2017.07.006
Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance
Bhargavi Pulluri (2017)
10.1007/978-3-319-22539-5_16
Novel Treatments in Development for Melanoma.
C. Bernatchez (2016)
10.1038/s41591-019-0476-5
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
A. Ribas (2019)
10.2478/raon-2014-0035
Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib
S. Valpione (2015)
10.1146/annurev-med-112311-083918
Harnessing the power of the immune system to target cancer.
G. Lizée (2013)
10.1158/1078-0432.CCR-14-2339
The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
L. Liu (2015)
10.3389/fimmu.2019.00386
The Ins and Outs of Chemokine-Mediated Immune Cell Trafficking in Skin Cancer
A. O. Yam (2019)
10.1016/j.bcp.2013.11.013
Emerging insights into resistance to BRAF inhibitors in melanoma.
A. Bucheit (2014)
10.1016/S0140-6736(20)30934-X
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
R. Gutzmer (2020)
10.1080/10428194.2017.1370548
Regulation of MAPK signaling and implications in chronic lymphocytic leukemia
Ashima Shukla (2018)
10.1517/13543784.2013.797964
Phase I/II RAF kinase inhibitors in cancer therapy
S. Turajlic (2013)
10.1007/164_2017_5
Immunotolerance as a Mechanism of Resistance to Targeted Therapies in Melanoma.
M. Mandala (2018)
10.1016/j.humpath.2014.04.001
Molecular pathology of malignant melanoma: changing the clinical practice paradigm toward a personalized approach.
Joshua R. Bradish (2014)
10.1177/1060028014544165
Controversies in the Management of Advanced Melanoma
A. Jarkowski (2014)
10.1053/j.seminoncol.2015.02.008
Anti-PD-1 therapy in melanoma.
B. Homet Moreno (2015)
10.1007/s10555-014-9542-0
Immunotherapy of melanoma: Present options and future promises
Anand Rotte (2014)
10.1158/1078-0432.CCR-18-0720
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma
Y. Yan (2019)
10.1016/j.molonc.2014.07.014
The immune‐related role of BRAF in melanoma
S. Tomei (2015)
10.1016/B978-0-12-394296-8.00025-7
Immunotherapy and Cancer Therapeutics: A Rich Partnership
G. Chen (2013)
10.1158/1078-0432.CCR-13-0261
Adoptive T-cell Transfer Therapy and Oncogene-Targeted Therapy for Melanoma: The Search for Synergy
M. L. Kwong (2013)
10.1007/s00403-014-1457-7
Targeting the PD-1 pathway: a promising future for the treatment of melanoma
A. Mamalis (2014)
10.3892/ol.2020.11365
Upregulation of microRNA-31 is associated with poor prognosis in patients with advanced colorectal cancer
Nobuhito Kubota (2020)
10.1158/2159-8290.CD-14-0477
Universes collide: combining immunotherapy with targeted therapy for cancer.
J. Wargo (2014)
10.1038/s41591-019-0448-9
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
P. Ascierto (2019)
10.1016/j.ejca.2017.03.012
Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients.
D. Massi (2017)
10.1177/2515135519862234
Therapeutic vaccination immunomodulation: forming the basis of all cancer immunotherapy
B. J. Coventry (2019)
10.2217/mmt-2016-0029
Are we entering the era of combination therapy for melanoma?
Justine V Cohen (2017)
BiomarkersforImmunostimulatoryMonoclonalAntibodiesin C ombination S trateg ies for Melanoma and O th er T umor T yp es
P. Ascierto (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar